Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation

Launched by UNIVERSITAS PADJADJARAN · Feb 28, 2013

Keywords

ClinConnect Summary

Introduction:

In a recent clinical trial the investigators have shown that a higher dose of rifampicin administered intravenously (600 mg iv) during the first 2 weeks of treatment is safe and associated with a survival benefit in adults with TB meningitis. An oral (rather than iv) dose would help implementation of intensified treatment for TB meningitis. However, it is hard to predict what oral dose of rifampicin will result in rifampicin exposures similar to 600 mg iv, due to differences in bio-availability (oral vs. iv) and the unpredictable dose-concentration relationship (nonlinear pha...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Probable/possible tuberculosis meningitis using uniform case definition
• • Agree to participate in the study
• Exclusion Criteria:
• • Patient with antituberculosis treatment within last 2 weeks.
• • Increase liver function \>5x upper limit of normal
• • Pregnancy